Abstract 2453
Background
Recent development in cancer care challenges the earlier and more linear care trajectory. This implies an increased need for symptom management and support. In research on intensity of care at end-of-life (EOL), there is a trend to increased utilization of health, such as re-admissions, emergency admissions and to intensive care (ICU). Previous research has investigated factors such as gender, socio-economic status, comorbidities and type of disease. Research on symptoms leading to hospitalizations reveal that more than half of symptoms were related to disease and 30% to side-effects from treatment. Some research reveals that symptom burden in hospitalized patients may be associated with hospital length of stay (LOS) and re-admissions. This study aims to analyze the relationship between Health-Related Quality of Life (HRQoL) and different aspects of health care utilization, such as; LOS, re-admissions within 30 days and unplanned care.
Methods
Survey data using the European Organization for Research and Treatment of Cancer (EORTC QLQ C30) tool on HRQoL were linked data from the Swedish Cancer Quality registries and the database for health care utilization. Patients with a complex care trajectory (in this study Gynecology, Head & Neck, Hematology and Upper GI cancer) were included. Functional scales and symptom scales from EORTC QLQ C30 were analyzed for correlations with LOS, re- admissions within 30 days and unplanned care. Independent variables are patient demographics and clinical variables such as; treatment and/or type of treatment, performance status, co-morbidities and referral to palliative care.
Results
In total, 1872 patients responded to the survey (response rate 64 %), 41 % men and 59 % women (mean age 67 years). The number of patients in each group are; Gynecological (n 598), Hematological (n 461), Head & Neck (n 395) and Upper GI cancers (n 418). Analysis are currently ongoing with multivariate regression models and will be presented in the poster/oral presentation.
Conclusions
On possible correlations between different factors related to aspects of care utilization will be presented.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
This investigation and study was supported by grants from the Cancer Research Foundation in Northern Sweden.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
5705 - External validation and longitudinal extension of the LIPI (Lung Immune Prognostic Index) for immunotherapy outcomes in advanced non-small cell lung cancer.
Presenter: Jakob Riedl
Session: Poster Display session 3
Resources:
Abstract
5758 - Changes of TCR Repertoire in Metastatic Renal Cell Carcinoma and Metastatic Melanoma Patients Treated with Nivolumab
Presenter: Martin Klabusay
Session: Poster Display session 3
Resources:
Abstract
1743 - Expression of MHC class I, HLA-A and HLA-B identifies immune activated breast tumors with favorable outcome
Presenter: María Del Mar Noblejas López
Session: Poster Display session 3
Resources:
Abstract
2219 - Prognostic Significance of Tumor Tissue NeuGcGM3 Ganglioside Expression and Predictive Value of Circulating Tumor Cell Count Monitoring in Patients Receiving Racotumomab Immunotherapy
Presenter: Necdet Üskent
Session: Poster Display session 3
Resources:
Abstract
2996 - Evolution of Myeloid-Derived Suppressor Cells and Objective Response Rate in Relapsed/Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL) patients after receiving immunotherapy
Presenter: Carlos Jiménez Cortegana
Session: Poster Display session 3
Resources:
Abstract
2110 - A Phase Ia/Ib trial of the anti-programmed death-ligand 1 (PD-L1) human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumors or lymphomas
Presenter: Lin Shen
Session: Poster Display session 3
Resources:
Abstract
3515 - Results from a randomised Phase 1/2 trial evaluating the safety and antitumour activity of anti-PD-1 (MEDI0680)/anti-PD-L1 (durvalumab) vs anti-PD-1 (nivolumab) alone in metastatic clear cell renal cell carcinoma (ccRCC)
Presenter: Martin Voss
Session: Poster Display session 3
Resources:
Abstract
3566 - Pembrolizumab in Advanced Rare Cancers
Presenter: Aung Naing
Session: Poster Display session 3
Resources:
Abstract
3567 - High clinical benefit rates of pembrolizumab in very rare sarcoma histotypes: first results of the AcSé Pembrolizumab study
Presenter: Jean-Yves Blay
Session: Poster Display session 3
Resources:
Abstract
2421 - Lenvatinib plus PD-1 blockade in advanced bile tract carcinoma.
Presenter: Jianzhen Lin
Session: Poster Display session 3
Resources:
Abstract